Amgen today announced that results from the Repatha (evolocumab) OSLER-1 study, were published inJAMA Cardiology. Repatha, when added to standard of care, achieved median low-density lipoprotein cholesterol reductions of 57 percent at four years, with no new safety concerns identified and no neutralizing antibodies observed with cumulative exposure.
Amgen has announced positive top-line results from a Phase 3 study evaluating Repatha (evolocumab) in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol (LDL-C). The study met its primary endpoint, demonstrating that treatment with Repatha significantly reduced the need for LDL-C apheresis in adult patients, as measured at the end of the randomized period.
Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, maximally reducing low-density lipoprotein cholesterol levels with Repatha, beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations.
Detailed results of the Repatha (evolocumab) cardiovascular outcomes trial will be presented, as well as new data from across the cardiovascular portfolio, at the American College of Cardiology 66th Annual Scientific Session (ACC.17) in Washington, D.C., March 17-19, 2017.
- Results to be Presented as Late-Breaking Oral Presentation - Largest International Trial Conducted in Multiple Myeloma - Study Met Primary Endpoint of Non-Inferiority Versus Zoledronic Acid in Delaying Bone Complications Known as Skeletal-Related Events
Världens första fas III-studie som jämför proteasomhämmare visar att Kyprolis förbättrar den totala överlevnaden signifikant jämfört med Velcade hos patienter med myelom. – Vi vet från tidigare studier att Kyprolis förlänger tiden till nästa återfall i sjukdomen, men nu ser vi också en substantiell skillnad i total överlevnad, säger Cecilie Hveding Blimark, Sahlgrenska Universitetssjukhuset.
Amgen has announced that the FOURIER trial evaluating whether Repatha (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina or coronary revascularization).
Amgen today announced the JAMA publication of findings from three Phase 3 studies of Parsabiv (etelcalcetide), an investigational intravenous calcimimetic agent. The studies evaluated Parsabiv in adults with secondary hyperparathyroidism (sHPT) on hemodialysis and showed that the drug produced statistically significant and clinically meaningful reductions in serum parathyroid hormone (PTH) levels.
De första resultaten från fas III-studien ’482 visar att Xgeva är lika effektivt som bisfosfonater när det gäller att fördröja skelettkomplikationer vid myelom. – Många myelompatienter lider av nedsatt njurfunktion och kan därför inte behandlas med bisfosfonater. För dessa patienter är de här resultaten mycket hoppingivande, säger Michael Grövdal, hematolog och medicinsk rådgivare vid Amgen.
Tillägg av antikroppen Vectibix till cytostatika ger signifikant förbättrad total överlevnad vid spridd tjocktarmscancer hos patienter där tumören inte har muterad RAS-gen. Nya retrospektiva analyser som presenterats vid ESMO-kongressen som pågår i Köpenhamn visar att detta är extra tydligt för de patienter som har tumör som uppstått i vänster del av tjocktarmen.
Enligt en internationell studie vars resultat nu publicerats i vetenskapstidskriften Journal Of Clinical Oncology (JCO) har läkemedlet Blincyto visat sig ha god effekt på barn med akut lymfatisk leukemi av B-cellstyp (B-ALL). ALL är den vanligaste typen av cancer hos barn.
Amgen has announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of carfilzomib, melphalan and prednisone (KMP) versus bortezomib, melphalan and prednisone (VMP) with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem-cell transplant. The trial did not meet the primary endpoint of superiority in progression-free survival (PFS).
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.se
Gustav III:s Boulevard 54
169 27 Solna
Sverige